Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Anesth Analg ; 129(6): 1504-1511, 2019 12.
Article in English | MEDLINE | ID: mdl-31743169

ABSTRACT

BACKGROUND: Dexmedetomidine provides smooth and hemodynamically stable emergence at the expense of hypotension, delayed recovery, and sedation. We investigated the optimal dose of dexmedetomidine for prevention of cough, agitation, hypertension, tachycardia, and shivering, with minimal side effects. METHODS: In this prospective, randomized, double-blind trial, 216 adult patients were randomly assigned to dexmedetomidine 1 µg/kg (D 1), 0.5 µg/kg (D 0.5), 0.25 µg/kg (D 0.25), or control (C). During emergence, cough, agitation, hemodynamic parameters, shivering, time to extubation, and sedation scores were recorded. RESULTS: A total of 190 patients were analyzed. The respective incidences for the groups D 1, D 0.5, and D 0.25 versus group C were 48%, 64%, and 64% vs 84% for cough-corrected P < .003 between groups D 1 and C; 33%, 34%, and 33% vs 72% for agitation-corrected P < .003 between group C and each of the study groups; and 4%, 2%, and 7% vs 22% for shivering-corrected P = .03 and corrected P = .009 between groups D 1 and D 0.5 versus group C, respectively. The percent increase from baseline blood pressure on extubation for the 3 treatment groups was significantly lower than group C. Percent increase in heart rate was lower than control in groups D 1 and D 0.5 but not in group D 0.25. Time to extubation and sedation scores were comparable. However, more hypotension was recorded during the emergence phase in the 3 treatment groups versus group C. CONCLUSIONS: D 1 at the end of surgery provides the best quality of emergence from general anesthesia including the control of cough, agitation, hypertension, tachycardia, and shivering. D 0.5 also controls emergence phenomena but is less effective in controlling cough. The 3 doses do not delay extubation. However, they cause dose-dependent hypotension.


Subject(s)
Adrenergic alpha-2 Receptor Agonists/administration & dosage , Anesthesia Recovery Period , Anesthesia, General , Dexmedetomidine/administration & dosage , Hypnotics and Sedatives/administration & dosage , Adolescent , Adrenergic alpha-2 Receptor Agonists/adverse effects , Adult , Aged , Anesthesia, General/adverse effects , Cough/prevention & control , Dexmedetomidine/adverse effects , Dose-Response Relationship, Drug , Double-Blind Method , Emergence Delirium/prevention & control , Female , Humans , Hypertension/prevention & control , Hypnotics and Sedatives/adverse effects , Hypotension/chemically induced , Lebanon , Male , Middle Aged , Prospective Studies , Shivering/drug effects , Tachycardia/prevention & control , Time Factors , Treatment Outcome , Young Adult
2.
Rev Mal Respir ; 36(1): 1-6, 2019 Jan.
Article in French | MEDLINE | ID: mdl-30638790

ABSTRACT

INTRODUCTION: This study analyzes the relationship between the occurrence of spontaneous pneumothorax and atmospheric pressure. PATIENTS AND METHODS: We conducted a retrospective study on 74 patients hospitalized for spontaneous pneumothorax in the department of respiratory diseases from the Ibn Roshd university hospital of Casablanca between January 2013 and June 2014. The value of atmospheric pressure at the time of the occurrence of pneumothorax was recorded and analyzed. RESULTS: The mean age was 46 years with 70 men and 4 women. Eighty-one percent of patients were smokers and 89% lived in an urban zone. Overall, 79.7% of pneumothoraces occurred in anticyclonic conditions, with a median atmospheric pressure of 1018 hPa±4.18. In all, 12.2% of pneumothoraces occurred in atmospheric depression with a median atmospheric pressure of 1010 hPa±1.92. The remaining 8.1% occurred in isobaric conditions. Pneumothoraces occurred significantly more during periods of high pressure compared to other periods (P<0.001; odds ratio: 28.41; relative risk 6.56 [3.52

Subject(s)
Atmospheric Pressure , Pneumothorax/etiology , Respiratory Physiological Phenomena , Aged , Female , Humans , Male , Middle Aged , Morocco , Retrospective Studies , Risk Factors
3.
J Arthroplasty ; 34(2): 333-337, 2019 02.
Article in English | MEDLINE | ID: mdl-30459008

ABSTRACT

BACKGROUND: The dual mobility cups (DMCs) were shown to reduce dislocation rate following total hip arthroplasty for any etiology, including femoral neck fractures. No reported studies evaluating DMC results for femoral neck fracture in a Middle Eastern population were found in the literature. METHODS: This study aims to look for mortality rate, clinical, and functional outcomes in a population having specific rituals involving extreme hip positions as part of their daily activities. RESULTS: Of an initial sample of 174 patients (177 operated hips), 18 (10.3%) patients (20 hips) died after a mean of 39.6 ± 13.8 months (ranging from 2 to 49 months) with only 3 (1.7%) during the first post-operative year. Twelve patients (13 hips) were lost to follow-up and 19 patients (19 hips) had their radiological data incomplete. In the final sample of 125 patients (125 hips), no dislocation, aseptic loosening, or infection was encountered. The mean modified Hip Harris Score was of 94.8 ± 8.4. The mean modified Hip Harris Score of 40 patients who used to practice regularly oriental sitting position or prayers was 94.1 ± 3.1. After surgery, 36 of these 40 patients (90%) described their hip as "a forgotten hip." Multivariate analyses found correlation only between mortality and cardiovascular co-morbidities. CONCLUSION: DMC implants showed excellent clinical and functional results. The majority of patients having rituals and customs involving extreme hip positions were able to resume their daily activities. The observed low mortality rate should incite future research to investigate its correlation with the use of DMCs.


Subject(s)
Arthroplasty, Replacement, Hip/instrumentation , Arthroplasty, Replacement, Hip/mortality , Femoral Neck Fractures/surgery , Hip Prosthesis , Aged , Aged, 80 and over , Female , Humans , Joint Dislocations , Lebanon/epidemiology , Male , Middle Aged , Prosthesis Design , Prosthesis Failure , Range of Motion, Articular , Reoperation , Retrospective Studies
4.
Rev Pneumol Clin ; 73(2): 55-60, 2017 Apr.
Article in French | MEDLINE | ID: mdl-28162798

ABSTRACT

BACKGROUND/AIM: The endobronchial tuberculosis (EBTB) is an uncommon type of tuberculosis. The respiratory symptoms in EBTB are usually nonspecific and misleading. The aim of the study is to determine the clinical features and diagnostic aspects of EBTB. PATIENTS AND METHODS: Twenty-eight cases of endobronchial tuberculosis collected from January 2009 to October 2015. RESULTS: EBTB was found in 16 females and 12 males. The mean age was 48 years. The history of tuberculosis and tuberculosis contagion were not found in any case. The respiratory symptoms were dominated by cough and dyspnea. Hemoptysis was found in 7 cases. The chest X-ray showed associated pulmonary lesions in 26 cases. Bronchoscopy finded an endobronchial granular lesion in 15 cases, a tumorous pattern in 7 cases; a thickening spurs in 4 cases and ganglio-bronchial fistula in two cases. Bronchial biopsies had found a caseo-follicular tuberculosis in 27 cases. Pleural biopsy confirmed associated pleural tuberculosis in one case. The research of Koch bacillus in the sputum was positive in 13 cases and culture in 6 cases. The antituberculosis treatment was started in all patients and an oral corticosteroids treatment was associated in 5 cases. The evolution was good in 26 cases. CONCLUSION: This study showed clinical, radiological and endoscopic bronchial tuberculosis polymorphism making its diagnosis difficult and the importance of a bacteriological and/or histological confirmation.


Subject(s)
Bronchial Diseases , Tuberculosis, Pulmonary , Adolescent , Adult , Aged , Antitubercular Agents/therapeutic use , Bronchial Diseases/diagnosis , Bronchial Diseases/drug therapy , Bronchial Diseases/epidemiology , Bronchoscopy , Diabetes Complications/diagnosis , Diabetes Complications/drug therapy , Diabetes Complications/epidemiology , Female , Humans , Male , Middle Aged , Morocco/epidemiology , Retrospective Studies , Smoking/epidemiology , Socioeconomic Factors , Tuberculosis, Pulmonary/diagnosis , Tuberculosis, Pulmonary/drug therapy , Tuberculosis, Pulmonary/epidemiology , Young Adult
6.
Anesth Analg ; 124(2): 438-444, 2017 02.
Article in English | MEDLINE | ID: mdl-28002167

ABSTRACT

BACKGROUND: Haloperidol is an antipsychotic. At low doses, it is a useful agent for the prophylaxis of postoperative nausea and vomiting (PONV). However, its use for treating established PONV has not been well studied. METHODS: This randomized double-blinded trial tested whether haloperidol is noninferior to ondansetron for the early treatment of established PONV in adult patients undergoing general anesthesia. The primary outcome is whether patients were PONV free during the first 4 hours. The noninferiority margin was set at 15%. One hundred twenty patients with PONV received either haloperidol 1 mg intravenously (n = 60) or ondansetron 4 mg intravenously (n = 60). RESULTS: Data from 112 patients (59 in the haloperidol group and 53 in the ondansetron group) were analyzed. Thirty-five patients (52%) in the haloperidol group received 1 or 2 prophylactic antiemetics compared with 42 (79%) in the ondansetron group. Haloperidol was noninferior to ondansetron for the end point of complete response to treatment (defined as the rate of PONV-free patients) for the early (0-4 hour) and the 0- to 24-hour postoperative periods by both the per-protocol and intention-to-treat analyses. In the per-protocol analysis, complete responses in the early period were noted in 35 of 59 patients (59%) and 29 of 53 patients (55%) for the haloperidol and ondansetron groups, respectively (difference 5%; 95% confidence interval [CI]: -13% to 22 %), and in the 0- to 24-hour period in 31 of 59 patients (53%) and 26 of 53 patients (49%) for the haloperidol and ondansetron groups, respectively (difference 4%; 95% CI of the difference: -15% to 21%). In the intention-to-treat analysis, complete responses in the early period were noted in 35 of 60 patients (58%) and 29 of 60 patients (48%) for the haloperidol and ondansetron groups, respectively (difference 10%; 95% CI of difference: -8% to 27%) and in the 0- to 24-hour period in 31 of 60 patients (52%) and 26 of 60 patients (43%) for the haloperidol and ondansetron groups, respectively (difference 8%; 95% CI of the difference: -9% to 25%). All other PONV secondary outcomes were comparable. Twenty-five percent of patients in the haloperidol group were sedated versus 2% in the ondansetron group (P < .001; difference 23%; 95% CI of the difference: 11%-36%). Pain, satisfaction scores, need for analgesics, and changes in QTc intervals were not different between the 2 groups. CONCLUSIONS: Haloperidol is at worst 13% and 8% less effective than ondansetron by per-protocol analysis and by intention-to-treat analysis, respectively. Thus, it is noninferior to ondansetron for the early treatment of established PONV, but is associated with sedation.


Subject(s)
Anesthesia, General/adverse effects , Antiemetics/therapeutic use , Haloperidol/therapeutic use , Ondansetron/therapeutic use , Postoperative Nausea and Vomiting/drug therapy , Administration, Intravenous , Adult , Aged , Antiemetics/adverse effects , Double-Blind Method , Electrocardiography/drug effects , Female , Haloperidol/adverse effects , Humans , Kaplan-Meier Estimate , Male , Middle Aged , Ondansetron/adverse effects , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...